An Integrated Methodology for Mining Promiscuous Proteins: A Case Study of an Integrative Bioinformatics Approach for Hepatitis C Virus Non-structural 5a Protein

Author(s):  
Mahmoud M. ElHefnawi ◽  
Aliaa A. Youssif ◽  
Atef Z. Ghalwash ◽  
Wessam H. El Behaidy
2002 ◽  
Vol 9 (1) ◽  
pp. 16-36 ◽  
Author(s):  
Samiha El Katsha ◽  
Susan Watts ◽  
Awatif Younis ◽  
Shukrayia Labib ◽  
Amal el Bedawi ◽  
...  

2019 ◽  
Vol 42 (9) ◽  
pp. 555-556
Author(s):  
Montserrat Laguno ◽  
Maria Martínez-Rebollar ◽  
Lorena de la Mora ◽  
Sofía Pérez-del-Pulgar ◽  
Josep Mallolas

2021 ◽  
Author(s):  
Željko Vujović

Abstract The aim of this paper was to consider the reliability of the basic metrics of evaluation of classification models: accuracy, sensitivity, specificity and precision. The WEKA software tool was applied to the "Hepatitis C virus (HCV) for Egyptian patients dataset". The algorithms Bayesnet, Naivebayesh, Multilayer Perceptron, J48 and 10-fold cross validation were used in the study. The main results obtained are that, with all four algorithms in question, they achieved approximately the same accuracy of correctly classified specimens. BaiesNet - 22.96%, NaiveBaies - 26.14%, MultilaierPerceptron - 26.57% and J48 - 25.27%. Binary classification metrics - sensitivity, specificity and precision show very different values, depending on the intended class. Metric specificity, for all four algorithms, shows that a value that is in most of the range of possible values ​​[0,1]. Metric sensitivity and precision, for all four algorithms, showed values ​​that are in the lower part of the range of possible values ​​[0,1]. The results of this study showed that WEKA software could not yet be considered as a relevant tool for the diagnosis of Hepatitis C Virus, on whose data set it was applied.


2019 ◽  
Vol 70 (1) ◽  
pp. e747-e748 ◽  
Author(s):  
Victor De Ledinghen ◽  
Bureau christophe ◽  
Yuri Sanchez ◽  
Fabrice Ruggeri ◽  
Pierre-Henri Delaage ◽  
...  

Author(s):  
Maya Leventer-Roberts ◽  
Noa Dagan ◽  
Jenna M Berent ◽  
Ilan Brufman ◽  
Moshe Hoshen ◽  
...  

Abstract Background Most studies estimate hepatitis C virus (HCV) disease prevalence from convenience samples. Consequently, screening policies may not include those at the highest risk for a new diagnosis. Methods Clalit Health Services members aged 25–74 as of 31 December 2009 were included in the study. Rates of testing and new diagnoses of HCV were calculated, and potential risk groups were examined. Results Of the 2 029 501 included members, those aged 45–54 and immigrants had lower rates of testing (12.5% and 15.6%, respectively), higher rates of testing positive (0.8% and 1.1%, respectively), as well as the highest rates of testing positive among tested (6.1% and 6.9%, respectively). Discussion In this population-level study, groups more likely to test positive for HCV also had lower rates of testing. Policy makers and clinicians worldwide should consider creating screening policies using on population-based data to maximize the ability to detect and treat incident cases.


2007 ◽  
Vol 1 ◽  
pp. 1177391X0700100 ◽  
Author(s):  
K.-C. Cheng ◽  
Walter A. Korfmacher ◽  
Ronald E. White ◽  
F. George Njoroge

Lead optimization using drug metabolism and pharmacokinetics (DMPK) parameters has become one of the primary focuses of research organizations involved in drug discovery in the last decade. Using a combination of rapid in vivo and in vitro DMPK screening procedures on a large array of compounds during the lead optimization process has resulted in development of compounds that have acceptable DMPK properties. In this review, we present a general screening paradigm that is currently being used as part of drug discovery at Schering-Plough and we describe a case study using the Hepatitis C Virus (HCV) protease inhibitor program as an example. By using the DMPK optimization tools, a potent HCV protease inhibitor, SCH 503034, was selected for development as a candidate drug.


2018 ◽  
Vol 68 ◽  
pp. S174-S175 ◽  
Author(s):  
M. Cornberg ◽  
Y. Sanchez ◽  
A. Pangerl ◽  
H. Razavi

Sign in / Sign up

Export Citation Format

Share Document